EUVIMEDEUVIMED entdecken
Crossref

Design of Multi‐Epitope DIVA ‐Compatible Vaccine Candidate Against Canine Parvovirus 2

Shubham Sharma, Pratishtha Sharma, Ravindra Pal Mandar, Ram Kumar, Ashok Gaur, Mamta Gurjar, Rajesh Singathia, Braj Nandan Shringi, Sunita Choudhary, Amit Kumar Pandey iD

Journal of Molecular Recognition · 2026-05 · 39 (3)

DOI: 10.1002/jmr.70036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Recognition, online erschienen am 23.04.2026. Verfasst von Shubham Sharma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Pharmacology, RAJUVAS, Bikaner, Rajasthan, India. Hauptthemen laut MEDLINE: Parvovirus, Canine, Viral Vaccines, Epitopes, T-Lymphocyte, Parvoviridae Infections. Die Arbeit nennt 66 Literaturangaben. Gefördert von: Department of Science and Technology, Govt. of Rajasthan (SP-36.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Canine parvovirus type 2 (CPV‐2) is a highly contagious and often fatal canine pathogen, with antigenic variants (CPV‐2a, 2b, 2c), maternally derived antibody (MDA) interference, and lack of Differentiating Infected from Vaccinated Animals (DIVA) capability limiting current vaccines. Using an immunoinformatics‐based reverse vaccinology approach, we identified conserved B‐cell, cytotoxic T lymphocyte (CTL), and helper T lymphocyte (HTL) epitopes from CPV‐2 structural (VP1, VP2) and nonstructural (NS1, NS2) proteins. These were screened for antigenicity, immunogenicity, safety, and stability. The screening identified three B‐cell, two CTL, and five HTL epitopes. Out of these, two representative epitopes were utilized for in vitro evaluation. The peripheral blood mononuclear cells (PBMCs) were collected from 10 dogs 28 days after vaccination with a live‐attenuated whole‐virus CPV vaccine and pooled. This pool was expected to contain memory cytotoxic T cells recognizing a broad viral epitope repertoire. On antigenic stimulation, PCPV2 induced significant proliferation of canine PBMCs, with the highest response at 33.33 μg/mL, alongside ~15.67‐fold upregulation of IFN‐γ mRNA, indicating a memory T‐cell response. A multi‐epitope vaccine was designed by integrating validated epitopes with the TLR‐4 agonist RS09 and a Capripoxvirus‐derived DIVA marker, linked by AAY/EAAAK spacers. The vaccine construct can be effectively delivered via a recombinant canine adenovirus‐2 vector for efficient in vivo expression and cellular response. Structural modeling, molecular docking, immune simulations, molecular dynamic simulations, and codon optimization predicted strong receptor binding, stability, IgG/T‐cell responses, and expression feasibility in Escherichia coli and canine cells. These findings support PCPV2 as a potent immunogen and demonstrate the promise of the designed construct for a potential adenovirus‐vectored vaccine; however, in vivo validation will be essential to confirm efficacy, cross‐variant protection, and DIVA performance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parvovirus, CanineViral VaccinesEpitopes, T-LymphocyteParvoviridae InfectionsEpitopes, B-LymphocyteEpitopesDog DiseasesAnimalsDogsT-Lymphocytes, CytotoxicReverse VaccinologyLeukocytes, MononuclearProtein Subunit VaccinesT-Lymphocytes, Helper-Inducer

Stichwörter der Autor:innen

DIVA vaccinecanine parvovirus 2immunoinformaticsin vitro evaluationmulti‐epitope vaccinereverse vaccinology

Substanzen

Viral VaccinesEpitopes, T-LymphocyteEpitopes, B-LymphocyteEpitopesProtein Subunit Vaccines

Autor:innen und Institutionen

  • Department of Veterinary Pharmacology, RAJUVAS, Bikaner, Rajasthan, India.
  • Department of Veterinary Microbiology, RAJUVAS, Bikaner, Rajasthan, India.
  • Center for Ethno-Veterinary Practice and Alternative Medicines (CEVPAM), RAJUVAS, Bikaner, Rajasthan, India.
  • Vaccinology and Biological Products Center (VBPRC), RAJUVAS, Bikaner, Rajasthan, India.
  • Department of Veterinary Medicine, RAJUVAS, Bikaner, Rajasthan, India.
  • Department of Veterinary Biochemistry, RAJUVAS, Bikaner, Rajasthan, India.

ORCID-Profile: Amit Kumar Pandey

Förderung

  • Department of Science and Technology, Govt. of Rajasthan (SP-36

Zitieren

APA

Sharma, S., Sharma, P., Mandar, R. P., Kumar, R., Gaur, A., Gurjar, M., Singathia, R., Shringi, B. N., Choudhary, S., & Pandey, A. K. (2026). Design of Multi‐Epitope DIVA ‐Compatible Vaccine Candidate Against Canine Parvovirus 2. Journal of Molecular Recognition, 39(3). https://doi.org/10.1002/jmr.70036

Vancouver

Sharma S, Sharma P, Mandar RP, Kumar R, Gaur A, Gurjar M, et al. Design of Multi‐Epitope DIVA ‐Compatible Vaccine Candidate Against Canine Parvovirus 2. Journal of Molecular Recognition. 2026;39(3). doi:10.1002/jmr.70036

BibTeX
@article{Sharma2026,
  author = {Sharma, Shubham and Sharma, Pratishtha and Mandar, Ravindra Pal and Kumar, Ram and Gaur, Ashok and Gurjar, Mamta and Singathia, Rajesh and Shringi, Braj Nandan and Choudhary, Sunita and Pandey, Amit Kumar},
  title = {Design of Multi‐Epitope DIVA ‐Compatible Vaccine Candidate Against Canine Parvovirus 2},
  journal = {Journal of Molecular Recognition},
  year = {2026},
  volume = {39},
  number = {3},
  doi = {10.1002/jmr.70036}
}
Kostenlos starten →